News

Call to Action – NIH Technology Accelerator Challenge for Maternal Health – up to $1 Million in Cash Prizes!

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is proud to announce the launch of the NIH Technology Accelerator Challenge for Maternal Health (NTAC: Maternal Health) in conjunction with the White House Maternal Health Day of Action. 

NTAC: Maternal Health is offering up to $1,000,000 in cash prizes to reward the development of low-cost, point-of-care molecular, cellular, and/or metabolic sensing and diagnostic technologies to guide rapid clinical decision-making, improve patient outcomes, and ultimately prevent maternal morbidity and mortality. More broadly, the NTAC series of prize competition’s goals are to stimulate the design of new diagnostic technologies to transform public and global health and accelerate the full development of those products urgently needed for use in low-resource settings. Device prototypes submitted to NTAC: Maternal Health should be capable of full integration with digital health platforms and be able to diagnose at least two pregnancy-associated conditions, including infections, hypertensive disease, hemorrhage, or placental issues. Complete challenge details can be found at https://www.nibib.nih.gov/research-program/NIH-Technology-Accelerator-Challenge-Maternal-Health-Announcement .

Participants in NTAC: Maternal Health will compete for the first-place prize of up to $500,000, a second-place prize of up to $300,000, and a third-place prize of up to $150,000, with the potential for additional awards of $50,000 for semi-finalists as well as honorable mention recognitions. Additionally, the Bill & Melinda Gates Foundation is collaborating with NIH and will separately review winners and honorable mentions to consider them for follow-on support that may include grant funding and/or in-kind support in the form of consultations and partnerships for clinical data collection, software development, scale-up, and manufacturing. This Challenge is also co-sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the NIH Office of Research on Women’s Health.

The Challenge sponsors will host an Informational Webinar for any interested participants on January 13, 2022, from 12:00 pm-1:00 pm ET. Participants wishing to compete in NTAC: Maternal Health must register for the Challenge by April 1, 2022, at https://venturewell.org/ntac/. Submissions will begin to be accepted on January 5, 2022, and must be submitted by April 22, 2022. In case of any questions, send an email to NIBIBChallenge@mail.nih.gov .

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and